zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Æxlishemjandi lyf - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
havrix stungulyf, dreifa 1440 elisa ein./ml
glaxosmithkline pharma a/s - lifrarbólguveira a (deydd) - stungulyf, dreifa - 1440 elisa ein./ml
flixotide innúðalyf, dreifa 50 míkróg/skammt
glaxosmithkline pharma a/s - fluticasonum própíónat - innúðalyf, dreifa - 50 míkróg/skammt
flixotide innúðalyf, dreifa 250 míkróg/skammt
glaxosmithkline pharma a/s - fluticasonum própíónat - innúðalyf, dreifa - 250 míkróg/skammt
flixotide innúðalyf, dreifa 125 míkróg/skammt
glaxosmithkline pharma a/s - fluticasonum própíónat - innúðalyf, dreifa - 125 míkróg/skammt
bactroban smyrsli 20 mg/g
glaxosmithkline pharma a/s - mupirocinum inn - smyrsli - 20 mg/g
bactroban nasal nefsmyrsli 20 mg/g
glaxosmithkline pharma a/s - mupirocinum kalsíum - nefsmyrsli - 20 mg/g
betnovat húðlausn 1 mg/ml
glaxosmithkline pharma a/s - betamethasonum valerat - húðlausn - 1 mg/ml
dermovat húðlausn 0,5 mg/ml
glaxosmithkline pharma a/s - clobetasolum própíónat - húðlausn - 0,5 mg/ml
dermovat smyrsli 0,5 mg/g
glaxosmithkline pharma a/s - clobetasolum própíónat - smyrsli - 0,5 mg/g